Biogen (BIIB) Stock Forecast & Price Target

Compare

4,996 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BIIB Analyst Ratings

Moderate Buy

11 Buy

14 Hold

1 Sell

Based on 26 analysts giving stock ratings to

Biogen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$206.23

▲(4.94% Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $206.23 with a high forecast of $246.00 and a low forecast of $143.00. The average price target represents a 4.94% change from the last price of $196.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"119":"$119","151":"$151","183":"$183","215":"$215","247":"$247"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":246,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$246.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":206.22727272727272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$206.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$143.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[119,151,183,215,247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.09,184.2369230769231,189.38384615384615,194.53076923076924,199.67769230769233,204.82461538461538,209.97153846153847,215.11846153846153,220.26538461538462,225.4123076923077,230.55923076923077,235.70615384615385,240.8530769230769,{"y":246,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.09,181.17748251748253,183.26496503496503,185.35244755244756,187.43993006993006,189.52741258741258,191.6148951048951,193.7023776223776,195.78986013986014,197.87734265734264,199.96482517482517,202.0523076923077,204.1397902097902,{"y":206.22727272727272,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.09,176.31384615384616,173.5376923076923,170.76153846153846,167.98538461538462,165.20923076923077,162.43307692307692,159.65692307692308,156.88076923076923,154.10461538461539,151.32846153846154,148.5523076923077,145.77615384615385,{"y":143,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":143.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$246.00

Average Price Target$206.23

Lowest Price Target$143.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Amsellem

Piper Sandler

$177

Hold

-9.93%

Downside

Reiterated

02/18/26

Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)

Salim Syed

Mizuho Securities

$207→$236

Buy

20.09%

Upside

Reiterated

02/11/26

Biogen price target raised to $236 from $207 at MizuhoBiogen price target raised to $236 from $207 at Mizuho

Paul Matteis

Stifel Nicolaus

$202→$214

Buy

8.89%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Biogen (NASDAQ: BIIB) and Quest Diagnostics (NYSE: DGX)

Andrew Fein

H.C. Wainwright

$194→$228

Buy

16.02%

Upside

Reiterated

02/09/26

Biogen price target raised to $228 from $194 at H.C. WainwrightBiogen price target raised to $228 from $194 at H.C. Wainwright

Terence Flynn

Morgan Stanley

$156→$190

Hold

-3.32%

Downside

Reiterated

02/09/26

Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating

Evan Seigerman

BMO Capital

$165→$196

Hold

-0.26%

Downside

Reiterated

02/09/26

Biogen price target raised to $196 from $165 at BMO CapitalBiogen price target raised to $196 from $165 at BMO Capital

Mohit Bansal

Wells Fargo

$190→$200

Hold

1.77%

Upside

Reiterated

02/09/26

Biogen price target raised to $200 from $190 at Wells FargoBiogen price target raised to $200 from $190 at Wells Fargo

Geoff Meacham

Citi

$185→$215

Hold

9.40%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC) and Biogen (NASDAQ: BIIB)

Laura Chico

Wedbush

$178→$187

Hold

-4.84%

Downside

Reiterated

02/09/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Danielle Brill

Truist Financial

$190→$193

Hold

-1.79%

Downside

Reiterated

02/09/26

Biogen price target raised to $193 from $190 at TruistBiogen price target raised to $193 from $190 at Truist

Salveen Richter

Goldman Sachs

$225→$231

Buy

17.55%

Upside

Reiterated

02/09/26

Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity

Phil Nadeau

TD Cowen

$175→$215

Buy

9.40%

Upside

Reiterated

02/09/26

Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating

Yatin Suneja

Guggenheim

$185→$246

Buy

25.18%

Upside

Reiterated

02/08/26

Biogen price target raised to $246 from $185 at GuggenheimBiogen price target raised to $246 from $185 at Guggenheim

Myles Minter

William Blair

Buy

―

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Biohaven Ltd. (NYSE: BHVN) and Adaptive Biotechnologies (NASDAQ: ADPT)

Ami Fadia

Needham

Hold

―

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Biogen (NASDAQ: BIIB)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Amsellem

Piper Sandler

$177

Hold

-9.93%

Downside

Reiterated

02/18/26

Piper Sandler Keeps Their Hold Rating on Biogen (BIIB)

Salim Syed

Mizuho Securities

$207→$236

Buy

20.09%

Upside

Reiterated

02/11/26

Biogen price target raised to $236 from $207 at MizuhoBiogen price target raised to $236 from $207 at Mizuho

Paul Matteis

Stifel Nicolaus

$202→$214

Buy

8.89%

Upside

Reiterated

02/10/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Biogen (NASDAQ: BIIB) and Quest Diagnostics (NYSE: DGX)

Andrew Fein

H.C. Wainwright

$194→$228

Buy

16.02%

Upside

Reiterated

02/09/26

Biogen price target raised to $228 from $194 at H.C. WainwrightBiogen price target raised to $228 from $194 at H.C. Wainwright

Terence Flynn

Morgan Stanley

$156→$190

Hold

-3.32%

Downside

Reiterated

02/09/26

Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating

Evan Seigerman

BMO Capital

$165→$196

Hold

-0.26%

Downside

Reiterated

02/09/26

Biogen price target raised to $196 from $165 at BMO CapitalBiogen price target raised to $196 from $165 at BMO Capital

Mohit Bansal

Wells Fargo

$190→$200

Hold

1.77%

Upside

Reiterated

02/09/26

Biogen price target raised to $200 from $190 at Wells FargoBiogen price target raised to $200 from $190 at Wells Fargo

Geoff Meacham

Citi

$185→$215

Hold

9.40%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Centene (NYSE: CNC) and Biogen (NASDAQ: BIIB)

Laura Chico

Wedbush

$178→$187

Hold

-4.84%

Downside

Reiterated

02/09/26

Wedbush Keeps Their Hold Rating on Biogen (BIIB)

Danielle Brill

Truist Financial

$190→$193

Hold

-1.79%

Downside

Reiterated

02/09/26

Biogen price target raised to $193 from $190 at TruistBiogen price target raised to $193 from $190 at Truist

Salveen Richter

Goldman Sachs

$225→$231

Buy

17.55%

Upside

Reiterated

02/09/26

Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity

Phil Nadeau

TD Cowen

$175→$215

Buy

9.40%

Upside

Reiterated

02/09/26

Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating

Yatin Suneja

Guggenheim

$185→$246

Buy

25.18%

Upside

Reiterated

02/08/26

Biogen price target raised to $246 from $185 at GuggenheimBiogen price target raised to $246 from $185 at Guggenheim

Myles Minter

William Blair

Buy

―

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Biohaven Ltd. (NYSE: BHVN) and Adaptive Biotechnologies (NASDAQ: ADPT)

Ami Fadia

Needham

Hold

―

Reiterated

02/06/26

Analysts Offer Insights on Healthcare Companies: McKesson (NYSE: MCK) and Biogen (NASDAQ: BIIB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months

xxx

Success Rate

13/22 ratings generated profit

Average Return

+0.99%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +0.99% per trade.

1 Year

Marc GoodmanLeerink Partners

Success Rate

16/35 ratings generated profit

Average Return

+2.32%

a rating ―

Copying Marc Goodman's trades and holding each position for 1 Year would result in 45.71% of your transactions generating a profit, with an average return of +2.32% per trade.

2 Years

xxx

Success Rate

11/22 ratings generated profit

Average Return

+1.93%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +1.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BIIB has received 23 Buy Ratings, 29 Hold Ratings, and 2 Sell Ratings. BIIB average Analyst price target in the past 3 months is 206.23.

Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.04 with a range of $1.66 to $4.68. The previous quarter’s EPS was $1.99. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.25B with a range of $2.13B to $2.43B. The previous quarter’s sales results were $2.18B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?

Based on analyst ratings, Biogen’s 12-month average price target is 206.23.

What is BIIB’s upside potential, based on the analysts’ average price target?

Biogen has 4.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BIIB a Buy, Sell or Hold?

Biogen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 14 hold ratings and 1 sell ratings.

What is Biogen’s price target?

The average price target for Biogen is 206.23. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $246.00 ,the lowest forecast is $143.00. The average price target represents 4.94% Increase from the current price of $196.52.

What do analysts say about Biogen?

Biogen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of BIIB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Biogen (BIIB) Stock Forecast & Price Target

BIIB Analyst Ratings

BIIB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Biogen

BIIB Analyst Recommendation Trends

BIIB Financial Forecast

BIIB Earnings Forecast

BIIB Sales Forecast

BIIB Stock Forecast FAQ

Detailed List of Analyst Forecasts